The study, which will enroll adult patients with HAE type I or II, will estimate the safety, pharmacokinetics and pharmacodynamics of various doses of C1-INH.
CSL Behring clinical research and development senior vice president Russell Basser said, "Subcutaneous administration of C1-esterase inhibitor will represent another important advance for patients suffering from the frequent and often debilitating attacks of HAE."
The open-label study is a part of Clinical studies for Optimal Management in Preventing Angioedema with Low-Volume Subcutaneous C1-Inhibitor Replacement Therapy program.